E
E. Drescher
Publications - 19
Citations - 1138
E. Drescher is an academic researcher. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 7, co-authored 14 publications receiving 883 citations.
Papers
More filters
Journal ArticleDOI
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados,Désirée van der Heijde,Ying-Chou Chen,Maria Greenwald,E. Drescher,Jiajun Liu,Scott D. Beattie,Sarah Witt,Inmaculada de la Torre,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,Stephanie de Bono,Paul Emery +13 more
TL;DR: In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.
Journal ArticleDOI
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Désirée van der Heijde,Atul Deodhar,James Cheng-Chung Wei,E. Drescher,Dona Fleishaker,Thijs Hendrikx,David Li,Sujatha Menon,Keith S. Kanik +8 more
TL;DR: Tofacitinib 5 and 10 mg twice daily demonstrated greater clinical efficacy versus placebo in reducing signs, symptoms and objective endpoints of active AS in adult patients with a similar 12-week safety profile as reported in other indications.
Journal ArticleDOI
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone,Peter C. Taylor,E. Drescher,Douglas E Schlichting,Scott D. Beattie,Pierre-Yves Berclaz,Chin Lee,Rosanne Fidelus-Gort,Monica E. Luchi,Terence Rooney,William L. Macias,Mark C. Genovese +11 more
TL;DR: Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease and was well tolerated with no unexpected safety findings through week 24.
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
Paul P. Tak,Andra Balanescu,Vira Tseluyko,Silvia Bojin,E. Drescher,Dan Dairaghi,Shichang Miao,Vittorio Marchesin,Juan C. Jaen,Thomas J. Schall,Pirow Bekker +10 more
TL;DR: CCX354-C exhibited a good safety and tolerability profile and evidence of clinical activity in RA, and was generally well tolerated by study subjects.